Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy prostate instrument
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy prostate instrument
复制标题
DOI：
10.1016/s0090-4295(97)00459-7
复制
发表时间：
1997-12-01
期刊：
影响因子：
2.1
通讯作者：
Pienta, KJ
中科院分区：
文献类型：
--
作者：
Esper, P;Mo, F;Pienta, KJ
目标。 1997 年，美国前列腺癌发病率超过 330,000 例，越来越多的男性面临着没有明确方法的治疗选择。在疾病的每个阶段，这些治疗选择可能涉及临床上等效的方式，但副作用和对生活质量 (QOL) 的影响有所不同。需要全面而有效的问卷来测量前列腺癌患者的生活质量。 方法，作为癌症治疗功能评估 (FACT) 测量系统的疾病特异性辅助手段，开发了 12 项前列腺癌子量表 (PCS)，并在三个独立样本中进行测试：子量表开发样本 (n = 43)、有效性样本 1 (n = 34) 和有效性样本 2(n = 96）。这 12 项询问了前列腺癌特有的症状和问题。这些问题被添加到通用 (FACT-G) 工具中，从而组成一个包含 47 项的调查问卷。结果，PCS 的内部一致性范围为 0.65 至 0.69，FACT-G 子量表的系数和聚合分数范围为 0.61 至 0.90。通过疾病阶段、体力状态和基线前列腺特异性抗原 (PSA) 水平区分患者的能力证实了同时有效性。对 2 个月内体能状态和 PSA 评分变化的敏感性表明，FACT-前列腺 (P) 的某些分量表（包括 PCS）对有意义的临床变化很敏感。结论。我们的研究结果支持使用 FACT-P 作为接受前列腺癌治疗的男性生活质量评估的一个有意义的组成部分。 (C) 1997，Elsevier Science Inc. 保留所有权利。
Objectives. As the incidence of prostate cancer in the United States exceeds 330,000 in 1997, increasingly more men are faced with treatment choices for which there is no clear approach. At every stage of disease, these treatment choices may involve clinically equivalent modalities that differ in side effects and impact upon quality of life (QOL). Comprehensive, yet efficient, questionnaires are needed to measure QOL in patients with prostate cancer.Methods, Developed as a disease-specific adjunct to the Functional Assessment of Cancer Therapy (FACT) measurement system, a 12-item prostate cancer subscale (PCS) was developed and tested in three independent samples: a subscale development sample (n = 43), validity sample 1 (n = 34), and validity sample 2(n = 96). The 12 items ask about symptoms and problems specific to prostate cancer. These questions are added to the general (FACT-G) instrument, thereby comprising a 47-item questionnaire,Results, Internal consistency of the PCS ranged from 0.65 to 0.69, with coefficients for FACT-G subscales and aggregated scores ranging from 0.61 to 0.90. Concurrent validity was confirmed by the ability to discriminate patients by disease stage, performance status, and baseline prostate-specific antigen (PSA) level. Sensitivity to change in performance status and PSA score over a 2-month period suggested that some subscales of the FACT-Prostate (P) (including the PCS) are sensitive to meaningful clinical change.Conclusions. Our findings support use of the FACT-P as a meaningful component of QOL evaluation in men undergoing therapy for prostate cancer. (C) 1997, Elsevier Science Inc. All rights reserved.